Trend
DailyUptrend (starting)
4 hourSymmetric Triangle
1 hourStrong Bearish
15 minSymmetric Triangle
5 minStrong Bearish
Daily trend turns down below $0.86
Key levels
Resistance$1.42
Resistance$1.20
Support$1.03
Support$0.86
Latest news & SEC filings
No headlines in the last 90 days.
ALX Oncology is a biotech firm in the clinic stage that works on treatments for people with cancer. Its main drug, evorpacept, blocks CD47 and is studied alongside other tumor-fighting medicines, including trastuzumab, in breast and stomach cancers. A second drug, ALX2004, pairs an EGFR binder with a payload to attack solid tumors. Trials run in the United States and other countries.
Based on the company's 10-K filed Mar 9, 2026.
Nasdaq · Healthcare
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ALXO.
Start Free Trial →Valuation Verdict
OVERVALUED
Methods Used
P/B, PEG
Fair Value
$0.93
9
Moat Score
NONE
1/9
Piotroski Score
-21.3
Altman Z-Score
Insider Signal
NEUTRAL
1 buys / 3 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
DISTRIBUTING
Short Squeeze Risk
LOW
Signal: NEUTRAL
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
26.36%
FCF Growth YoY
31.1%
Revenue Trend
UNKNOWN
SEPT Investing tracks real-time dark pool institutional trades for ALXO, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 19:12:52 | $1.04 | 2,400 | $$2K | BUY |
| 19:12:35 | $1.02 | 2,500 | $$3K | BUY |
| 19:09:39 | $1.02 | 1,000 | $$1K | BUY |
| 18:44:27 | $1.01 | 2,650 | $$3K | SELL |
| 18:38:59 | $1.02 | 9,000 | $$9K | MIDPOINT |
5 dark pool trades shown · $$18K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for ALX ONCOLOGY HOLDINGS INC (ALXO) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ALX ONCOLOGY HOLDINGS INC (ALXO) is at $1.03, down 4.17% (-$0.05) at the Nov 13, 2026 close.
Analyst ratings for ALXO: 6 Buy, 1 Hold, 0 Sell — consensus Strong Buy.
ALXO last reported on Aug 6, 2026: EPS -$0.13 vs -$0.14 expected — a beat of 9.0%.
ALXO does not currently pay a dividend.
ALX ONCOLOGY HOLDINGS INC reported $10M of debt and $23M of cash (Jun 30, 2026).
Support: $1.03, $0.86, $0.66. Resistance: $1.20, $1.42, $1.61.
Insider activity: NEUTRAL, 1 buys and 3 sells in the last 90 days.